Doublet Immunotherapy Disappoints in Gastric Cancer Study
The findings, in which doublet immunotherapy added to standard FOLFOX chemotherapy did not improve progression-free survival, underscore the importance of PD-L1 expression in immunotherapy trials.
Medscape Medical News
source https://www.medscape.com/viewarticle/doublet-immunotherapy-disappoints-gastric-cancer-study-2024a1000gpz?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/doublet-immunotherapy-disappoints-gastric-cancer-study-2024a1000gpz?src=rss
Comments
Post a Comment